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Peroxisome proliferator-activated receptor
expression is reduced in skeletal
muscle in COPD
A.H. Remels*, P. Schrauwen#, R. Broekhuizen*, J. Willems*, S. Kersten",
H.R. Gosker* and A.M. Schols*
ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a multiorgan systemic disease.
The systemic features are skeletal muscle weakness and cachexia, the latter being associated
with systemic inflammation. The exact mechanisms underlying skeletal muscle dysfunction in
COPD remain obscure. Recent evidence suggests involvement of the peroxisome proliferator-
activated receptors (PPARs) and PPAR-c coactivator (PGC)-1a in regulation of skeletal muscle
morphology and metabolism, and mitochondrial transcription factor A (TFAM) has been
implicated in the process of mitochondrial biogenesis. The aim of the present exploratory study
was, therefore, to compare these factors in the skeletal muscle of nine healthy control subjects
and 14 COPD patients stratified by cachexia.
PPAR-c, PPAR-d and TFAM were measured at the mRNA and protein level by real-time
quantitative PCR and Western blotting, respectively. PPAR-a and PGC-1a were meansured at the
mRNA level.
PPAR-d and TFAM protein content, as well as PGC-1a mRNA levels, were decreased in the
skeletal muscle of COPD patients compared with healthy controls. The cachectic COPD subgroup
was further characterised by decreased PPAR-a mRNA expression and decreased TFAM protein
and mRNA levels compared with noncachectic COPD patients. In addition, PPAR-a mRNA levels
in skeletal muscle correlated negatively with inflammatory markers in plasma.
Therefore, a disturbed expression of these regulatory factors may well underlie the disturbed
skeletal muscle functioning in chronic obstructive pulmonary disease.
KEYWORDS: Chronic obstructive pulmonary disease, mitochondrial transcription factor A,
peroxisome proliferator-activated receptors, peroxisome proliferator-activated receptor-c
coactivator-1a, skeletal muscle oxidative capacity
S
keletal muscle dysfunction has become a
recognised hallmark of chronic obstruct-
ive pulmonary disease (COPD). Although
it is obvious that impaired lung function inevi-
tably leads to reduced exercise tolerance in this
disorder, muscle dysfunction is probably an even
stronger determinant of exercise capacity, parti-
cularly in moderate-to-severe COPD [1]. More-
over, it has been convincingly shown that muscle
wasting is a strong predictor of mortality risk in
COPD, independent of the degree of airflow
limitation [2]. Since current bronchodilator and
anti-inflammatory medication primarily aimed at
improving lung function is rather ineffective in
reversing exercise intolerance, skeletal muscle
function may be an interesting alternative target
for novel therapies. Skeletal muscle dysfunction in
COPD is characterised by the loss of muscle
strength and endurance. The loss of muscle
endurance is associated with a type IRIIaRIIx
fibre-type shift, leading to decreased oxidative
capacity of the muscle [3]. The loss of muscle
strength is largely explained by the loss of muscle
mass due tocachexia, which is commonly observed
in moderate-to-severe COPD patients [4].
Other abnormalities pointing towards intrinsic
muscle abnormalities in COPD pathogenesis are
decreased content of substrates, such as specific
amino acids, increased oxidative stress and
decreased levels of uncoupling protein (UCP) 3,
a mitochondrial protein that serves as a putative
protector against lipid-induced mitochondrial
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damage [5–7]. In addition, COPD is also characterised by a
chronic systemic low-grade inflammatory status, which has
been suggested as a trigger for the loss of muscle mass and
muscle weakness [8, 9]. The exact molecular mechanisms and
key mediators involved in the loss of muscle strength and
endurance in COPD remain to be identified. The peroxisome
proliferator-activated receptors (PPARs), as well as PPAR-c
coactivator (PGC)-1a, a strong coactivator of PPAR transcrip-
tional activity, are key regulators of mitochondrial biogenesis
and hence of skeletal muscle oxidative capacity [10, 11].
Furthermore, they are potent mediators of a fibre-type shift of
type IIRI, and have been shown to possess anti-inflammatory
properties [12, 13]. Based on these findings, it was hypothe-
sised that expression of PPARs is reduced in the skeletal
muscle of COPD patients. Therefore, the aim of the present
study was to determine expression of the PPARs and PGC-1a
at the mRNA and protein level in skeletal muscle biopsy




The study population consisted of Dutch patients with
clinically stable Global Initiative for Chronic Obstructive
Lung Disease stage II–IV COPD (n514) and a group of healthy
age-matched controls (n59). All patients suffered from chronic
airflow limitation, defined as a measured forced expiratory
volume in one second (FEV1) ,70% of reference values.
Patients received standardised maintenance respiratory medi-
cation that consisted of inhaled bronchodilators, inhaled
corticosteroids and, when indicated, theophyllines. The exclu-
sion criteria were concurrent diseases, such as malignancies,
gastrointestinal or kidney abnormalities, metabolic or endo-
crine diseases and inflammatory diseases. Written consent was
obtained from all subjects, and the study was approved by the
ethical review board of Maastricht University Hospital
(Maastricht, the Netherlands).
Pulmonary function
FEV1 and forced vital capacity were assessed from the flow–
volume curve obtained using a spirometer (Masterlab; Jaeger,
Würzburg, Germany). Carbon monoxide diffusing capacity of
the lung was determined using the single-breath method
(Masterlab). Lung function parameters were expressed as a
percentage of reference values. Blood was drawn from the
brachial artery in order to analyse arterial oxygen and carbon
dioxide tension using a blood gas analyser (ABL 330;
Radiometer, Copenhagen, Denmark).
Blood sampling and tumour necrosis factor-a ELISA
Fasting blood was collected in evacuated blood collection tubes
containing ethylenediamine tetra-acetic acid (EDTA; Vacutainer
System; Becton Dickinson, Plymouth, UK) in the early
morning (08:00–10:00 h). After centrifuging twice for 10 min
at 1,0006g at 4uC within 2 h of collection, plasma samples
were stored at -80uC until analysis. Tumour necrosis factor
(TNF)-a levels were determined using the Quantikine high-
sensitivity ELISA (R&D Systems, Minneapolis, MN, USA),
with a lower detection limit of 0.5 pg?mL-1 for total TNF-a.
Levels of soluble 55-kDa TNF receptor (sTNF-R55) and
sTNF-R75 were measured in duplicate using the ELISA
protocol previously described by LEEUWENBERG et al. [14].
Body composition
Body mass index (BMI) was calculated from weight divided by
height in metres squared. Body composition was measured
using single-frequency (50 kHz) bioelectrical impedance analy-
sis (BIA; Xitron Technologies, San Diego, CA, USA) with
subjects in the supine position. The fat-free mass (FFM) of
patients was calculated using the disease-specific equation
proposed by SCHOLS et al. [15] and described by STEINER et al.
[16]. FFM index (FFMI) and fat mass (FM) index were
calculated from FFM or FM divided by height in metres
squared. Cachexia was defined as a BMI f21 kg?m-2 and FFMI
f16 kg?m-2 in male patients or f15 kg?m-2 in female patients.
Collection and processing of muscle tissue
Post-absorptive muscle biopsy specimens from the lateral part
of the quadriceps femoris were obtained under local anaes-
thesia using the needle biopsy technique. The specimens were
immediately snap-frozen in liquid nitrogen and stored at -80uC
until use.
Muscle oxidative phenotype
A 5% (weight/volume) homogenate was prepared by disper-
sion (Polytron1 PT 1600 E; Kinematica, Lucerne, Switzerland)
followed by sonication (Branson 2210; Branson Ultrasonics
Corporation, Danbury, CT, USA) of the tissue in 250 mM
sucrose, 2 mM EDTA, 10 mM tris(hydroxymethyl)amino-
methane (Tris; pH 7.4) for 1 min. The samples were centri-
fuged for 10 min at 10,0006g at 4uC. The supernatant was
used for determination of citrate synthase activity, as described
by GOSKER et al. [17]. The remaining pellet was resuspended in
three volumes of ice-cold extraction buffer (100 mM
Na4O7P2?10H2O (pH8.5), 5 mM EDTA, 1 mM dithiothreitol),
incubated on ice for 30 min and centrifuged for 10 min at
10,0006g at 4uC. The supernatant was used for myosin heavy
chain (MHC) isoform analysis. Electrophoresis gels were run
for 22 h using a Protean II xi Cell system (Bio-Rad, Veenendaal,
the Netherlands) at 20 mA, with voltage increasing to a
maximum of 350 V. Approximately 1.0 mg protein was loaded
per lane. The gels were silver-stained (Silver Stain Plus Kit;
Bio-Rad, Veenendaal, the Netherlands), scanned and photo-
graphed using a scanning densitometer (Fluor-S2
MultiImager; Bio-Rad), after which the protein bands were
quantified using Quantity One software (Bio-Rad). Levels of I,
IIa and IIx MHC isoforms were expressed relative to each
other.
Real-time quantitative PCR
Total RNA was extracted using the acid guanidium thiocya-
nate–phenol–chloroform extraction method (Ambion, Foster
City, CA, USA). RNA concentration was determined using a
spectrophotometer and quality was verified by agarose gel
electrophoresis. RNA (2 mg per sample) was reverse tran-
scribed to give complementary DNA (cDNA) according to the
manufacturer’s instructions (iScript RT kit; Bio-Rad, Hercules,
CA, USA). cDNA was PCR amplified using Platinum Taq DNA
polymerase (Invitrogen, Breda, the Netherlands) on a Bio-Rad
iCycler apparatus (Bio-Rad, USA). The primers were designed
to generate a PCR amplification product of 100–150 bp. The
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specificity of the amplification was verified by melt curve
analysis and evaluation of efficiency of PCR amplification.
Transcript levels of the constitutive housekeeping gene
product 36B4 were quantitatively measured in each sample
in order to control for sample-to-sample differences in RNA
concentration. Gene expression was quantified and expressed
in arbitrary units (AU).
Western blot analysis of protein expression
PPAR-d and mitochondrial transcription factor A (TFAM)
abundance were evaluated by Western blotting. Muscle biopsy
specimens were homogenised in PBS containing phenylmethy-
lsulphonyl fluoride (0.4 mM) and EDTA (1 mM) and sonicated
twice for 10 s at 12 mm and once for 5 s at 20 mm. Subse-
quently, the samples were diluted 2:1 in sample buffer con-
taining 2-mercaptoethanol and sodium dodecylsulphate and
boiled for 5 min. Equal amounts of protein were loaded on to a
10 and 12% (PPAR-d and TFAM, respectively) discontinuous
denaturating polyacrylamide gel, and electrophoresis was
performed using a Mini-PROTEAN 3 Electrophoresis Cell
system (Bio-Rad, USA). The primary antibodies, used accord-
ing to the manufacturer’s manual, included anti-PPAR-d
diluted 1:5,000 and anti-TFAM diluted 1:10,000 (both from
Santa Cruz, Santa Cruz, CA, USA). The secondary antibodies
(1:10,000) were rabbit anti-goat peroxidase and pig anti-rabbit
peroxidase (both from Dako Cytomation, Glostrup, Denmark).
Detection was performed using SuperSignal West Dura
Extended Duration Substrate (Pierce Boston Technology
Centre, Woburn, MA, USA) on a CL-Xposure Film (Pierce
Boston Technology Centre). Densitometric quantification was
performed using Image Master VDS (Amersham Pharmacia
Biotech, Uppsala, Sweden). A standard sample was included
in every blot in order to correct for blot-to-blot variation.
PPAR-d and TFAM content were both expressed in AU.
Statistical analysis
Data were analysed according to the guidelines of ALTMAN et
al. [18], using an unpaired t-test (corrected for unequal
variances as appropriate), one-way ANOVA (with an unpaired
t-test as the post hoc test) or Pearson’s correlation test, and with
nonparametric tests when appropriate. Data are presented as




The characteristics of the patients and control subjects are
summarised in table 1. No significant differences in age and
cumulative cigarette consumption (in pack-yrs) were observed
between patients and controls, providing a correction for
smoking behaviour between groups. Also, no significant
differences were observed between the lung function of
cachectic COPD patients and that of noncachectic patients.
Muscle fibre-type composition
The proportion of MHC type I tended to be lower in COPD
patients than in control subjects (24.6¡7.1 versus 30.6¡6.7%;
p50.114). There were no significant differences in the propor-
tions of MHC type IIa between patients and healthy controls.
The proportions of MHC type IIx was higher in patients than
in controls (30.4¡5.7 versus 19.4¡10.9%; p50.044; fig. 1). No
significant differences in fibre-type composition were observed
between cachectic and noncachectic patients.
PPAR-a
There were no significant differences in PPAR-a mRNA
expression in skeletal muscle from patients and control
subjects. However, a trend of lower PPAR-a mRNA levels in
patients than in controls was observed (1.39¡0.75 versus
1.87¡0.46 AU; p50.09; table 2). Interestingly, expression levels
of PPAR-a mRNA were .50% lower in cachectic COPD
patients than in noncachectic patients (0.87¡0.47 versus
2.14¡0.69 AU; p50.008) and healthy controls (1.87¡0.46 AU;
p50.004; fig. 2). In addition, PPAR-a mRNA levels in the
patient group correlated positively and significantly with BMI
(r50.700; p50.005) and FFMI (r50.593; p50.025). Although
several commercially available PPAR-a antibodies were tested,
none were of sufficient quality and specificity to detect PPAR-a
protein.
PPAR-d
There were no significant differences in the level of expression
of PPAR-d mRNA between patients and healthy control
subjects. A trend towards lower PPAR-d mRNA levels was
observed in skeletal muscle from cachectic versus noncachectic
patients (0.95¡0.33 versus 1.29¡0.28 AU; p50.085; table 2). At
the protein level, PPAR-d content was significantly lower in
TABLE 1 Subject characteristics
Controls COPD
Cachectic Noncachectic
M/F n 6/3 4/3 4/3
Age yrs 65¡4 58¡13 67¡9
Height cm 166.1¡7.6 168.0¡10.5 167.2¡7.2
Body composition
Weight kg 74.7¡10.4 59.0¡8.8# 72.5¡11.7
BMI kg?m-2 27.1¡3.7 20.1¡1.3# 27.0¡3.4
FFM kg 50.5¡9.1 43.2¡5.9" 48.8¡8.05
FFMI kg?m-2 18.0¡2.3 14.8¡0.7# 17.3¡2.2
FM kg 23.3¡8.1 15.8¡4.1" 23.7¡6.4
FMI kg?m-2 8.4¡3.5 5.4¡1.2# 8.9¡2.2
Lung function
FVC % pred 100.4¡20.5** 74.0¡15.4 79.8¡17.5
FEV1 % pred 117.2¡19.8** 38.8¡11.6 41.4¡18.5
DL,CO % pred 83.6¡29.2* 43.3¡18.8 60.9¡29.0
Smoking pack-yrs 35¡17 27¡14 35.7¡5
Pa,O2 kPa 9.7¡0.8 9.0¡1.5 9.4¡1.1
Pa,CO2 kPa 5.2¡0.4 5.3¡0.7 5.2¡0.9
Data are presented as mean¡SD, unless otherwise stated. COPD: chronic
obstructive pulmonary disease; M: male; F: female; BMI: body mass index;
FFM: fat-free mass; FFMI: fat-free mass index; FM: fat mass; FMI: fat mass
index; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory
volume in one second; DL,CO: diffusing capacity of the lung for carbon
monoxide; Pa,O2: arterial oxygen tension; Pa,CO2: arterial carbon dioxide tension.
#: p,0.01 versus noncachectic patients; ": p,0.05; *: p,0.05; **: p,0.01
versus COPD patients.
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skeletal muscle from COPD patients than from healthy control
subjects (1.67¡0.85 versus 2.64¡0.95 AU; p50.037; fig. 3a and b).
No significant differences in PPAR-d content were observed
between cachectic and noncachectic patients (fig. 3a).
PPAR-c
PPAR-c mRNA protein levels were too low to be detected in
skeletal muscle. PPAR-c could be detected in human adipose
tissue (as a positive control), but was below the detection limit
in the muscle samples (data not shown).
TFAM
No significant differences in TFAM mRNA expression levels
were found between patients and controls. However, TFAM
mRNA levels were significantly lower in cachectic than in
noncachectic patients (0.78¡0.27 versus 1.21¡0.25 AU; p50.013).
In addition, Western blot analysis revealed a significantly lower
content of TFAM in skeletal muscle from COPD patients than in
that from healthy controls (0.80¡0.36 versus 1.20¡0.13 AU;
p,0.001). Moreover, TFAM protein content was also signifi-
cantly lower in cachectic than in noncachectic patients
(0.60¡0.23 versus 0.95¡0.37 AU; p50.023; fig. 4).
PGC-1a
Expression of PGC-1a mRNA was lower in COPD patients
than in healthy controls (1.00¡0.49 versus 1.38¡0.23 AU;
p50.044; fig. 5). There were no differences in PGC-1a mRNA
level between cachectic and noncachectic patients. PGC-1a
protein content could not be assessed due to the lack of
commercially available high-quality antibodies.
Correlations
Correlation analysis was performed to investigate whether
PPAR expression levels or protein content were associated
with systemic inflammation, muscle oxidative capacity, muscle
fibre-type distribution or lung function. Expression levels of
PPAR-a mRNA correlated negatively with circulating levels of
TNF-a (r5 -0.576; p50.031; fig. 6). Similar results were found
for sTNF-R55 (r5 -0.606; p50.022) and sTNF-R75 (r5 -0.546;
p50.044). With regard to metabolic markers, PPAR-d and
PPAR-a mRNA levels in skeletal muscle correlated positively
with the oxidative enzyme citrate synthase (r50.587; p50.005,
and r50.463; p50.035, respectively). In addition, the propor-
tion of MHC type I fibres correlated positively and signifi-
cantly with skeletal muscle TFAM protein content (r50.554;
p50.014). No correlations were observed between PPAR
expression levels and lung function parameters.
DISCUSSION
COPD is characterised by reduced skeletal muscle function.
Muscle oxidative capacity is reduced, which is related to a
fibre-type shift from type I oxidative to type IIx glycolytic
fibres. In addition, the oxidative capacity within intermediary
type IIa fibres is also reduced [19, 20]. As the PPAR
transcription factors are involved in the regulation of muscular



















FIGURE 1. Fibre-type distribution in the quadriceps femoris of chronic
obstructive pulmonary disease patients (&; n513) and healthy control subjects
(h; n56). Data are presented as mean¡SD. MHC: myosin heavy chain. *: p,0.05
versus controls.
TABLE 2 mRNA expression levels in skeletal muscle
Controls COPD
Total Cachectic Noncachectic
PPAR-a 1.87¡0.46 1.39¡0.75 0.87¡0.47** 2.14¡0.69
PPAR-d 1.07¡0.17 1.12¡0.34 0.95¡0.33 1.29¡0.28
PPAR-c ND ND ND ND
TFAM 1.00¡0.27 1.00¡0.34 0.78¡0.27# 1.21¡0.25
PGC-1a 1.38¡0.23 1.00¡0.49* 0.89¡0.43 1.11¡0.56
Data are presented as mean¡SD arbitrary units. COPD: chronic obstructive
pulmonary disease; PPAR: peroxisome proliferator-activated receptor; TFAM:
mitochondrial transcription factor A; PGC: PPAR-c coactivator; ND: nondetect-
able. #: p,0.05; *: p,0.05 versus controls; **: p,0.01 versus noncachectic
patients.
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FIGURE 2. Box plot showing expression of peroxisome proliferator-activated
receptor (PPAR)-a mRNA in skeletal muscle from cachectic (n57) and noncachec-
tic (n57) chronic obstructive pulmonary disease COPD patients and healthy control
subjects (n59), controlled using 36B4 as housekeeping gene. Data are presented
as median¡SD (: interquartile range). AU: arbitrary unit. **: p,0.01.
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the skeletal muscle of COPD patients. In the present study it is
reported for the first time that PPAR-d protein content is
reduced in the skeletal muscle of COPD patients. Like PPAR-a,
PPAR-d is a strong positive regulator of skeletal muscle
oxidative metabolism as it is involved in the regulation of
proteins implicated in the uptake, handling and oxidation of
fatty acids, as well as other oxidative enzymes [11]. Indeed, in
the present study, PPAR-d and PPAR-a mRNA levels
correlated positively with the activity of the oxidative
tricarboxylic acid cycle enzyme citrate synthase, consistent
with involvement of these two PPAR subtypes in skeletal
muscle oxidative metabolism.
In addition to a decreased PPAR-d content, mRNA levels of
PGC-1a, a strong PPAR coactivator and key regulator of
mitochondrial biogenesis, were also reduced in the skeletal
muscle of these patients [21]. It has been shown that PPAR-d
and PGC-1a both have the ability to redirect fibre-type
distribution in skeletal muscle to a more oxidative phenotype
[11, 22, 23]. Given that COPD patients are characterised by an
increased amount of type IIx glycolytic fibres, it is tempting to
suggest that the reduction in PPAR-d and PGC-1a is causally
related to this fibre-type shift. Although no significant
correlations were found between PPAR, PGC-1a and fibre-
type composition, there was a significant positive correlation
between the PGC-1a-regulated TFAM and type I oxidative
fibres. Consistent with involvement of a reduced PPAR content
in the reduction in oxidative capacity in COPD is the finding
that UCP3 content is reduced in COPD [6]. Several reports
have shown that UCP3 is a PPAR-regulated gene [24].
Moreover, SCHRAUWEN et al. [25] reported that administration
of rosiglitazone, a potent PPAR-c agonist, restored muscular
UCP3 levels in diabetic patients. These observations further
strengthen the suggestion that PPARs play a role in skeletal
muscle abnormalities, as observed in COPD.
In addition to its regulatory role in skeletal muscle morph-
ology, PGC-1a is also involved in the regulation of TFAM,
which, in turn, controls the expression of mitochondrially
encoded genes involved in mitochondrial biogenesis and
respiration [26]. Interestingly, in the present study, a lower
expression of PGC-1a mRNA in skeletal muscle from COPD
patients was accompanied by a reduced TFAM protein content.
Thus reduced levels of PGC-1a may well be involved in the loss
of muscular oxidative capabilities in COPD. Intriguingly, in
other disease models, such as congestive heart failure and
diabetes mellitus, a decreased oxidative capacity of skeletal
muscle is also associated with decreased expression of PGC-1a
mRNA [27, 28]. Since there was a lack of specific antibodies, it
was not possible to verify whether or not PGC-1a levels were
indeed reduced in the skeletal muscle of COPD patients, but this
remains an interesting topic for future research.
Although a lower PPAR-d and TFAM protein content was
observed in the skeletal muscle of COPD patients, no
significant differences in the expression levels of PPAR-d or
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FIGURE 3. a) Expression of peroxisome proliferator-activated receptor
(PPAR)-d in skeletal muscle from cachectic (n57) and noncachectic (n57) chronic
obstructive pulmonary disease (COPD) patients and healthy control subjects (n59).
Data are presented as mean¡SD. AU: arbitrary unit. *: p,0.05 versus controls. b)
Representative Western blot analysis of PPAR-d (lanes 2 and 3: controls; lanes 4–7:
COPD patients). Equal amounts of protein were loaded in each lane and a standard
sample (lane 1) was included to correct for blot-to-blot variation. c) The specificity of
the antibody directed against human PPAR-d was tested by viral transfection of
human PPAR-d protein into neonatal rat cardiomyocytes (lane 1: 5,000 viral
particles?cell-1; lane 2: 10,000 viral particles?cell-1; lane 3: 25,000 viral particles?cell-1).
An increasing amount of virus resulted in an increasing intensity of both
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FIGURE 4. a) Mitochondrial transcription factor A (TFAM) protein content of
skeletal muscle from cachectic (n57) and noncachectic (n57) chronic obstructive
pulmonary disease (COPD) patients and healthy control subjects (n59). Data are
presented as mean¡SD. AU: arbitrary unit. *: p,0.05 versus noncachectic; ***:
p,0.001 versus controls. b) Representative Western blot analysis of TFAM (lanes 2
and 3: controls; lanes 4–8: COPD patients). Equal amounts of protein were loaded
in every lane and a standard sample (lane 1) was included to correct for blot-to-blot
variation. A 28-kDa band was identified as TFAM.
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patients and control subjects. This suggests the presence of a
post-transcriptional mechanism controlling PPAR-d and
TFAM protein levels in skeletal muscle. The interaction of
PPARs with specific pathways involved in protein degrada-
tion, e.g. the ubiquitin proteasome pathway, has been the
subject of limited investigation. Therefore, the identity and
nature of the post-transcriptional mechanism involved here
remains obscure. In addition, PPAR-c mRNA and protein were
undetectable in the present samples, supporting other reports
that, if present at all, PPAR-c content and expression in skeletal
muscle is very low.
Besides a disturbed oxidative phenotype, skeletal muscle
function in COPD is also severely impaired by muscle atrophy.
Strikingly, lower expression of PPAR-a mRNA was observed
in skeletal muscle from cachectic COPD patients than from
noncachectic patients and healthy controls. Also, PPAR-a
mRNA levels correlated negatively with circulating levels of
TNF-a and subunits of the TNF-a receptor in the current
COPD population. Systemic inflammation has been recognised
as an important risk factor for the loss of skeletal muscle mass
[8, 9]. Interestingly, there are also reports that describe a
negative effect of TNF-a on the activity of PPAR-a in vivo [29].
The present results confirm a link between PPAR-a and
inflammation-related cachexia, although the exact mechanisms
of the observed reduction are unclear and deserve further
investigation.
The reason for the decreased content or expression of PPARs in
skeletal muscle from COPD patients may be multifaceted. As
skeletal muscle is very responsive to metabolic and mechanical
influences, the observed reduction in PPAR-d and TFAM
protein content and the decreased gene expression of PGC-1a
and PPAR-a may represent an adaptation of the muscle cells
due to physiological and pathological changes, including
inactivity, hypoxia and inflammation. Furthermore, differences
in expression levels can be more pronounced in patients
suffering from the cachexia syndrome. A sedentary lifestyle,
which is often adopted by COPD patients due to disease-related
exercise limitations, could underlie the reduced protein
content of PPAR-d and reduced PGC-1a mRNA levels in
skeletal muscle, as it has been shown that PPAR-d and PGC-
1a are strongly upregulated by physical exercise [23, 30-32].
Hypoxia and inflammation, both commonly observed in
COPD, may also contribute to the lower PPAR expression
levels, as there are several reports that suggest a negative
influence of these parameters on PPAR expression levels [33,
34]. The specific contribution of these factors remains
unknown, and in vitro approaches should shed more light
on the involvement of hypoxia and inflammation in PPAR
expression levels and content. Intriguingly, diabetes mellitus
and congestive heart failure, diseases characterised by
systemic inflammation and increased levels of inactivity,
are also characterised by decreased muscular levels of PPAR
and/or PGC-1a, suggesting a prominent role for inflamma-
tion and physical activity level in controlling PPAR and
PGC-1a levels [27, 28, 35]. As the PPARs, and more
specifically PPAR-a and PPAR-d, are highly implicated in
skeletal muscle oxidative metabolism, which is obviously
impaired in COPD patients, they could serve as interesting
therapeutic targets. Increasing PPAR levels by means of
exercise, fatty acid supplementation and/or pharmacological
modulation could serve as a potential therapeutic strategy
for alleviating exercise intolerance in this disorder.
CONCLUSIONS
Reduced expression of peroxisome proliferator-activated
receptor-c coactivator-1a mRNA and a lower protein content
of peroxisome proliferator-activated receptor-d were found in
the lower limb skeletal muscle of chronic obstructive pulmon-
ary disease patients compared to healthy controls. In addition,
these reductions were accompanied by a decreased content of
mitochondrial transcription factor A. These findings imply
disturbed regulation of muscular oxidative capacity since
peroxisome proliferator-activated receptor-d, peroxisome
proliferator-activated receptor-c coactivator-1a and mitochon-


























FIGURE 5. Expression of peroxisome proliferator-activated receptor-c coacti-
vator (PGC)-1a mRNA in skeletal muscle from chronic obstructive pulmonary
disease (COPD) patients (n514) and healthy control subjects (n59), controlled
using 36B4 as housekeeping gene. Data are presented as mean¡SD. AU: arbitrary
unit. *: p,0.05 versus controls.
FIGURE 6. Correlation between blood circulatory levels of tumour necrosis
factor (TNF)-a and expression levels of peroxisome proliferator-activated receptor
(PPAR)-a mRNA in skeletal muscle from chronic obstructive pulmonary disease
patients. #: noncachectic; m: cachectic. AU: arbitrary unit. n514.
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ing skeletal muscle oxidative capacity. Therefore, disturbed
expression and/or content of these regulatory factors may well
underlie the disturbed skeletal muscle functioning in chronic
obstructive pulmonary disease. In addition, it is suggested that
not only the occurrence of the disease but also the presence of
cachexia and chronic inflammation affect peroxisome
proliferator-activated receptor mRNA and protein levels.
Since the explanation for a lower expression and content of
peroxisome proliferator-activated receptors and peroxisome
proliferator-activated receptor-d-related factors in skeletal
muscle from chronic obstructive pulmonary disease patients
is complex, further investigation is required to unravel the
exact mechanisms behind these observations.
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